Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Research Reports Coverage on Services Stocks -- Patterson, Booz Allen Hamilton, Owens & Minor, and Henry Schein

Chelmsford Park SA
Posted on: 24 Oct 16

NEW YORK, October 21, 2016 /PRNewswire/ -- has issued research reports on these four Services equities: Patterson Cos. Inc. (NASDAQ: PDCO), Booz Allen Hamilton Holding Corp. (NYSE: BAH), Owens & Minor Inc. (NYSE: OMI), and Henry Schein Inc. (NASDAQ: HSIC). According to the Headline Sales Managers' Index (SMI), business activity in the global sector rose 0.3 in September at 53.9. Meanwhile, the Business Confidence Index climbed in October, registering 58.1. These stocks research reports can be downloaded now by simply registering for free at:


On Thursday, shares in St. Paul, Minnesota headquartered Patterson Cos. Inc. recorded a trading volume of 1.02 million shares, which was above their three months average volume of 954,770 shares. The stock ended the session 0.77% lower at $44.05. The Company's shares are trading 2.40% below their 200-day moving average. Moreover, shares of Patterson Cos., which distributes and sells dental and animal health products in the US, the UK, and Canada, have a Relative Strength Index (RSI) of 38.57.

On October 11th, 2016, Patterson that Heartland Dental, the largest dental support organization in the U.S., has selected Patterson Dental as its distribution partner effective January 1st, 2017. Heartland Dental supports more than 1,100 dentists nationwide. Your complete research report on PDCO can be retrieved for free at:

Booz Allen Hamilton  

McLean, Virginia headquartered Booz Allen Hamilton Holding Corp.'s stock closed the day 0.40% higher at $30.29. A total volume of 973,210 shares was traded, which was above their three months average volume of 807,440 shares. The Company's shares are trading 4.11% above their 200-day moving average. Additionally, shares of Booz Allen Hamilton Holding, which provides management and technology, consulting, and engineering services to governments, corporations, and not-for-profit organizations in the US and internationally, have an RSI of 47.41.

On September 29th, 2016, Booz Allen Hamilton announced that it is updating its Sailfish platform. The company is leading commercial and government organizations to learn more from their data and to spur business and mission success. For the first time, users can try their own hand at analytics by accessing Booz Allen Hamilton's Sailfish trial that is fully available to the public.

On October 6th, 2016, research firm Raymond James upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. BAH free report is just a click away at:

Owens & Minor  

Shares in Mechanicsville, Virginia headquartered Owens & Minor Inc. recorded a trading volume of 291,461 shares, and ended yesterday's trading session 0.27% higher at $33.30. The stock is trading below its 50-day moving average by 1.59%. Shares of the Company, which together with its subsidiaries, operates as a healthcare logistics company, have an RSI of 44.93.

On October 19th, 2016, Owens & Minor announced plans to release financial results for Q3 2016 on November 1st, 2016, after the close of trading on the New York Stock Exchange. The company's executives will host a conference call which will also be webcast to discuss the results on the following morning November 2nd, 2016, at 8:30 a.m. EDT. Sign up for your complimentary research report on OMI at:

Henry Schein  

Melville, New York headquartered Henry Schein Inc.'s stock finished Thursday's session 0.78% lower at $152.85. A total volume of 571,769 shares was traded, which was above their three months average volume of 554,990 shares. The Company's shares are trading below their 50-day moving average by 5.54%. Additionally, shares of Henry Schein, which provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide, have an RSI of 34.14.

On October 14th, 2016, research firm Robert W. Baird downgraded the Company's stock rating from 'Outperform' to 'Neutral'. The research firm also revised downwards its previous target price from $176 to $164.

On October 19th, 2016, Henry Schein announced that its Board of Directors has authorized the repurchase of up to $400 million of shares of its common stock. This program is in addition to the $400 million repurchase program announced in December 2015. The Company had approximately 82 million shares outstanding as of July 27th, 2016, and this new authorization represents approximately 3.0% of shares outstanding at the day's stock price. Register for free on and download the latest research report on HSIC at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

For more information:

Editor's Details

Mike Wood

Last updated on: 24/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.